| Q34295462 | A computational physiology approach to personalized treatment models: the beneficial effects of slow breathing on the human cardiovascular system. |
| Q33983361 | ACE2-mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function |
| Q34784864 | ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good. |
| Q58744807 | Acute hydrocortisone administration reduces cardiovagal baroreflex sensitivity and heart rate variability in young men |
| Q37225431 | Angiotensin II type 1 receptor-mediated reduction of angiotensin-converting enzyme 2 activity in the brain impairs baroreflex function in hypertensive mice |
| Q37155907 | Angiotensin-converting enzyme 2 in the brain: properties and future directions |
| Q34423315 | Angiotensin-converting enzymes and drug discovery in cardiovascular diseases. |
| Q33639490 | Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension |
| Q36956571 | Cardiovascular responses to peripheral chemoreflex activation and comparison of different methods to evaluate baroreflex gain in conscious mice using telemetry |
| Q41956748 | Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension |
| Q39206260 | DOCA-Salt Hypertension: an Update |
| Q35314802 | In vivo assessment of neurocardiovascular regulation in the mouse: principles, progress, and prospects |
| Q44939750 | NADPH oxidase contributes to angiotensin II signaling in the nucleus tractus solitarius. |
| Q61920272 | Nicotine and the renin-angiotensin system |
| Q50672195 | Paris Prospective Study III: a study of novel heart rate parameters, baroreflex sensitivity and risk of sudden death. |
| Q36674343 | Reactive oxygen species in the neuropathogenesis of hypertension |
| Q57788882 | Should heart rate variability be "corrected" for heart rate? Biological, quantitative, and interpretive considerations |